Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of tofacitinib in active ankylosing spondylitis
NL-OMON40951Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib in ankylosing spondylitis (AS) (4 arms), sponsored by Pfizer. Primary endpoint: ASAS20 response rate at Week 12. Planned start Jun 2014; status: withdrawn.
02
Drugs
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON40951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40951.